Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 4NETWORK 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 11Breast Neoplasms, Male 2Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasm Female 1Breast Carcinoma In Situ 1

Interventions

Paclitaxel 3Docetaxel 3Watchful Waiting 2Tamoxifen 2Immunohistochemistry 2Goserelin 2Everolimus 2Cyclophosphamide 2Bevacizumab 2Anastrozole 2vandetanib 1pegfilgrastim 1lonafarnib 1exemestane 1Trastuzumab 1Sunitinib 1Psychiatric Rehabilitation 1Neoadjuvant Therapy 1Metformin 1Mental Status and Dementia Tests 1Leuprolide 1Letrozole 1Lapatinib 1High-Energy Shock Waves 1Gene Expression Profiling 1Doxorubicin 1Dasatinib 1Chemotherapy, Adjuvant 1Biopsy, Needle 1Amplified Fragment Length Polymorphism Analysis 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Breast Neoplasms, Male × Anastrozole × Clear all
NCT01674140 2026-02-10

e3

SWOG Cancer Research Network

Phase 3 Active not recruiting
1,939 enrolled 15 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT00217659 2013-01-03

S0511, Goserelin and Anastrozole in Treating Men With Recurrent or Metastatic Breast Cancer

SWOG Cancer Research Network

Phase 2 Withdrawn
Breast

Breast Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡